Point Biopharma Global Inc Reports Results For The Quarter Ended In June: Earnings Summary

POINT Biopharma Global

14/08/2023 14:32

* POINT Biopharma Global Inc  PNT.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
June. The mean expectation of eleven analysts for the quarter
was for a loss of 29 cents per share.
    * Revenue was $4.87 million​; analysts expected $944.44
thousand. 
    * POINT Biopharma Global Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * POINT Biopharma Global Inc shares had fallen by 0.8% this
quarter and gained 23.3% so far this year.
    * The company reported a quarterly loss of $25.41 million.
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.29          -0.24          Beat
 Mar. 31 2023      -0.31          -0.16          Beat
 Dec. 31 2022      -0.26                         
 Sep. 30 2022      -0.28          -0.26          Beat